临床开发新药肝癌药

StephenW

Reviews
Novel drugs in clinical development for hepatocellular carcinoma

August 2015, Vol. 24, No. 8 , Pages 1075-1082 (doi:10.1517/13543784.2015.1058776)

   
Oliver Waidmann, and Jörg Trojan
Universitätsklinikum Frankfurt, Medizinische Klinik 1, Theodor-Stern-Kai 7, Frankfurt am Main
, Germany +49 0 69 6301 7860; +49 0 69 6301 6448; [email protected]
†Author for correspondence


Introduction: Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Within recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development either due to toxicity or lack of benefit.

Areas covered: This review covers recent clinical data on systemic agents and ongoing trials in patients with advanced HCC.

Expert opinion: In unselected patients with advanced HCC, disappointing results have been reported from several large trials. However, in two subgroups encouraging results have been achieved. Treatment with the MET inhibitor tivantinib resulted in a substantial survival benefit in the subgroup of MET overexpressing tumors in a randomized Phase II trial. Furthermore, the vascular endothelial growth factor receptor 2 antibody ramucirumab resulted in improved overall survival in patients with baseline α-fetoprotein (AFP) ≥ 400 ng/ml in a Phase III trial. These two agents, and several others, will be further developed in HCC. Moreover, immunotherapeutics such as checkpoint inhibitors, programmed death receptor-1 blocking antibodies and oncolytic viruses are under investigation in advanced HCC.
Keywords
anti-CTLA-4, anti-PD1, cabozantinib, everolimus, hepatocellular carcinoma, immunotherapy, lenvatinib, oncolytic virus, ramucirumab, receptor tyrosine kinase inhibitor, refametinib, regorafenib, sorafenib, tivantinib, trebananib




Read More: http://informahealthcare.com/doi ... 543784.2015.1058776

StephenW

点评
新药的临床开发肝癌

2015年8月，卷。 24，8号，页1075至82年（DOI：10.1517 / 13543784.2015.1058776）

   
奥利弗Waidmann和约尔格木马
Universitätsklinikum法兰克福，Medizinische KLINIK 1，西奥多·斯特恩凯7，美因河畔法兰克福
，德国+49 0 69 6301 7860; +49 0 69 6301 6448; [email protected]
†作者的书信


简介：索拉非尼是批准用于治疗晚期肝细胞癌（HCC）治疗的唯一全身药物。在近年来，一些研究性药物主要是针对血管生成失败晚期阶段临床开发或者由于毒性或缺乏益处。

涵盖地区：该检讨的范围包括治疗晚期肝癌的系统性剂和正在进行的试验最近的临床数据。

专家观点：对于非指定患者的晚期肝癌，令人失望的结果已经报告从几个大的试验。然而，在两个分组令人鼓舞的结果已经实现。治疗与MET抑制剂tivantinib导致了过表达MET肿瘤的一项随机II期临床试验的亚组显着生存益处。此外，血管内皮细胞生长因子受体2抗体ramucirumab导致患者改善的总体存活与基线α甲胎蛋白（AFP）在III期临床试验≥400毫微克/毫升。这两种药物，和其他几个人，将进一步发展在肝癌。此外，免疫疗法等检查点抑制剂，程序性死亡受体1阻断抗体和溶瘤病毒正在调查中晚期肝癌。
关键词
抗-CTLA-4，抗PD1，cabozantinib，依维莫司，肝细胞癌，免疫疗法，lenvatinib，溶瘤病毒，ramucirumab，受体酪氨酸激酶抑制剂，refametinib，regorafenib，索拉非尼，tivantinib，trebananib




了解更多：http://informahealthcare.com/doi ... 543784.2015.1058776